USE OF CANNABIDIOL IN THE TREATMENT OF CHRONIC OROFACIAL PAIN: A LITERATURE REVIEW

Abstract

The use of cannabidiol (CBD), one of the main active compounds of Cannabis sativa, has generated growing interest in Dentistry, particularly in the management of chronic orofacial pain. These conditions, including temporomandibular disorders, neuralgias, and neuropathic pain, pose significant therapeutic challenges and are often resistant to conventional treatments. This study aims to provide an integrative and critical review of recent scientific evidence regarding the therapeutic application of cannabidiol in the control of chronic orofacial pain. The research is based on a bibliographic review of national and international studies published between 2020 and 2025, addressing the origin and composition of Cannabis sativa, its pharmacological properties, the mechanisms of the endocannabinoid system, and the ethical and legal aspects of medicinal cannabis use. The findings indicate that CBD exhibits relevant analgesic, anti-inflammatory, and anxiolytic properties, modulating nociceptive neurotransmission and reducing both peripheral and central sensitization associated with pain. Clinical evidence suggests that cannabidiol may represent a safe and effective alternative, particularly when used as an adjuvant therapy in combination with conventional approaches. However, standardized clinical protocols, longitudinal studies, and clearer regulations regarding dental applications are still needed. It is concluded that cannabidiol has promising therapeutic potential for the management of chronic orofacial pain, contributing to a more humanized, integrative, and patient-centered dental practice.